 Turning Point Therapeutics Inc NASDAQ: TPTX has reported initial data from the ongoing Phase 12 SWORD-1 study evaluating its RET inhibitor drug candidate, TPX-0046, in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. Data from the Phase 1 dose-finding portion of the study showed preliminary clinical activity, including objective responses and a generally well-tolerated safety profile. 